Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.

MLA

Xu, Yi-Xiang, et al. “Development of Disulfide-Derived Fructose-1,6-Bisphosphatase (FBPase) Covalent Inhibitors for the Treatment of Type 2 Diabetes.” European Journal of Medicinal Chemistry, vol. 203, Oct. 2020, p. 112500. EBSCOhost, https://doi.org/10.1016/j.ejmech.2020.112500.

APA

Xu, Y.-X., Huang, Y.-Y., Song, R.-R., Ren, Y.-L., Chen, X., Zhang, C., Mao, F., Li, X.-K., Zhu, J., Ni, S.-S., Wan, J., & Li, J. (2020). Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes. European Journal of Medicinal Chemistry, 203, 112500. https://doi.org/10.1016/j.ejmech.2020.112500

Chicago

Xu, Yi-Xiang, Yun-Yuan Huang, Rong-Rong Song, Yan-Liang Ren, Xin Chen, Chao Zhang, Fei Mao, et al. 2020. “Development of Disulfide-Derived Fructose-1,6-Bisphosphatase (FBPase) Covalent Inhibitors for the Treatment of Type 2 Diabetes.” European Journal of Medicinal Chemistry 203 (October): 112500. doi:10.1016/j.ejmech.2020.112500.